Labradimil | RMP 7 | CAS#159768-75-9 | bradykinin B2 receptor agonist

MedKoo Cat#: 326920 | Name: Labradimil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Labradimil, also known as RMP 7, is a bradykinin B2 receptor agonist potentially for the treatment of brain cancer. RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. RMP-7 enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. RMP-7 increases carboplatin levels in brain tumors after pretreatment with dexamethasone.

Chemical Structure

Labradimil

CAS#159768-75-9

Theoretical Analysis

MedKoo Cat#: 326920

Name: Labradimil

CAS#: 159768-75-9

Chemical Formula: C49H75N15O12S

Exact Mass: 1097.5440

Molecular Weight: 1098.29

Elemental Analysis: C, 53.59; H, 6.88; N, 19.13; O, 17.48; S, 2.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DRG-0182; DRG 0182; DRG0182; Receptor-mediated permeabiliser-7; RMP-7; RMP 7; RMP7; ALK-01-040; A 7; A 7 (peptide); Cereport; Lobradimil;

IUPAC/Chemical Name

(S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide

InChi Key

IDXCXSCCZNCXCL-XMADEQCMSA-N

InChi Code

InChI=1S/C49H75N15O12S/c1-76-31-14-12-28(13-15-31)21-29(24-57-34(47(74)75)9-3-17-56-49(53)54)59-43(70)37-10-4-18-62(37)45(72)36(27-65)61-41(68)35(23-32-7-6-20-77-32)60-40(67)25-58-42(69)39-22-30(66)26-64(39)46(73)38-11-5-19-63(38)44(71)33(50)8-2-16-55-48(51)52/h6-7,12-15,20,29-30,33-39,57,65-66H,2-5,8-11,16-19,21-27,50H2,1H3,(H,58,69)(H,59,70)(H,60,67)(H,61,68)(H,74,75)(H4,51,52,55)(H4,53,54,56)/t29-,30+,33-,34-,35-,36-,37-,38-,39-/m0/s1

SMILES Code

O=C([C@H]1N(CCC1)C([C@@H](N)CCCNC(N)=N)=O)N2[C@@H](C[C@H](C2)O)C(NCC(N[C@H](C(N[C@@H](CO)C(N3[C@@H](CCC3)C(N[C@H](CN[C@H](C(O)=O)CCCNC(N)=N)CC4=CC=C(C=C4)OC)=O)=O)=O)CC5=CC=CS5)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Chemical name: L-Arginine, L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolyl-O-methyl-L-tyrosyl-ψ(CH2-NH)-

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,098.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kuo YC, Lee CL. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf B Biointerfaces. 2012 Feb 1;90:75-82. doi: 10.1016/j.colsurfb.2011.09.048. Epub 2011 Oct 6. PubMed PMID: 22024400. 2: Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer. 2005 Nov 1;104(9):1968-74. PubMed PMID: 16177987. 3: Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005 Sep 15;104(6):1281-7. PubMed PMID: 16078267. 4: Zhang X, Xie Y, Jin Y, Hou X, Ye L, Lou J. The effect of RMP-7 and its derivative on transporting Evans blue liposomes into the brain. Drug Deliv. 2004 Sep-Oct;11(5):301-9. PubMed PMID: 15742555. 5: Zhang XB, Yuan S, Lei PC, Hou XP. [Therapeutic efficiency of amphotericin B liposome modified by RMP-7 to transport drug across blood brain barrier]. Yao Xue Xue Bao. 2004 Apr;39(4):292-5. Chinese. PubMed PMID: 15303662. 6: Zhang XB, Jin YG, Xie Y, Xu K, Hou XP. [Effect of RMP-7 and its derivatives on the transportation of liposome into the brain]. Yao Xue Xue Bao. 2003 Nov;38(11):867-70. Chinese. PubMed PMID: 14992004. 7: Prados MD, Schold SC JR SC, Fine HA, Jaeckle K, Hochberg F, Mechtler L, Fetell MR, Phuphanich S, Feun L, Janus TJ, Ford K, Graney W. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol. 2003 Apr;5(2):96-103. PubMed PMID: 12672281; PubMed Central PMCID: PMC1920676. 8: Grant R, Walker M, Hadley D, Barton T, Osborn C. Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not. J Neurooncol. 2002 May;57(3):241-5. PubMed PMID: 12125987. 9: Britz GW, Ghatan S, Spence AM, Berger MS. Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model. J Neurooncol. 2002 Feb;56(3):227-32. PubMed PMID: 12061728. 10: Warren KE, Patel MC, Aikin AA, Widemann B, Libucha M, Adamson PC, Neuwirth R, Benziger D, O'Toole T, Ford K, Patronas N, Packer RJ, Balis FM. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol. 2001 Oct;48(4):275-82. PubMed PMID: 11710627. 11: Dean RL, Emerich DF, Hasler BP, Bartus RT. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone. Neuro Oncol. 1999 Oct;1(4):268-74. PubMed PMID: 11550318; PubMed Central PMCID: PMC1920760. 12: Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH, Boddy AV. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. Cancer Chemother Pharmacol. 2000;45(4):284-90. PubMed PMID: 10755316. 13: Emerich DF, Dean RL, Marsh J, Pink M, Lafreniere D, Snodgrass P, Bartus RT. Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm Res. 2000 Oct;17(10):1212-9. PubMed PMID: 11145226. 14: Bartus RT, Snodgrass P, Marsh J, Agostino M, Perkins A, Emerich DF. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. J Pharmacol Exp Ther. 2000 Jun;293(3):903-11. PubMed PMID: 10869391. 15: Gregor A, Lind M, Newman H, Grant R, Hadley DM, Barton T, Osborn C. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. J Neurooncol. 1999 Sep;44(2):137-45. PubMed PMID: 10619497. 16: Shimuta SI, Barbosa AM, Borges AC, Paiva TB. Pharmacological characterization of RMP-7, a novel bradykinin agonist in smooth muscle. Immunopharmacology. 1999 Dec;45(1-3):63-7. PubMed PMID: 10614991. 17: Mackic JB, Stins M, Jovanovic S, Kim KS, Bartus RT, Zlokovic BV. Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharm Res. 1999 Sep;16(9):1360-5. PubMed PMID: 10496650. 18: Emerich DF, Snodgrass P, Dean R, Agostino M, Hasler B, Pink M, Xiong H, Kim BS, Bartus RT. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer. 1999 Jun;80(7):964-70. PubMed PMID: 10362103; PubMed Central PMCID: PMC2363031. 19: Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh G 4th, Chiocca EA, Breakefield XO. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. 1999 Jan-Feb;6(1):14-20. PubMed PMID: 10078959. 20: Cloughesy TF, Black KL, Gobin YP, Farahani K, Nelson G, Villablanca P, Kabbinavar F, Viñeula F, Wortel CH. Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurgery. 1999 Feb;44(2):270-8; discussion 278-9. PubMed PMID: 9932880.